Methotrexate in Metastatic Colorectal Cancer With MSH2 Deficiency

ABSTRACT: To assess the efficacy of methotrexate in a genetically selected population of patients with advanced colorectal cancer, who have loss of a particular gene, MSH2. The efficacy of methotrexate will be evaluated by the proportion of cases that have a significant response to treatment (objective response rate).

DISEASE(S): Colorectal Cancer,Colorectal Neoplasms,Advanced Colorectal Cancer

PROVIDER: 2076124 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR